Pyridodihydropyrazinone Kinase Inhibitors for Cell Cycle Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical compositions lack effective antiproliferative agents to address excessive or abnormal cell proliferation in diseases such as cancer, infections, and autoimmune disorders, particularly in inhibiting specific cell cycle kinases like PLK-1.
Innovation Solution
Development of pyridodihydropyrazinone compounds that act as inhibitors of specific cell cycle kinases, arresting cells in the mitosis phase and preventing programmed cell death, thereby offering antiproliferative activity for therapeutic use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If new pyridodihydropyrazinone compounds are developed to inhibit cell proliferation, then antiproliferative activity is improved, but compound complexity and synthesis difficulty increase
Solution Approach 1:
The pyridodihydropyrazinone compound structure is divided into distinct functional segments: a pyridine ring system, a dihydropyrazinone ring system, and various substituent groups (R1-R6). This segmentation allows for systematic modification of individual segments to optimize antiproliferative activity while managing structural complexity. The core bicyclic framework provides the essential kinase binding capability, while substituents fine-tune the activity profile.
Solution Approach 2:
The patent systematically varies multiple parameters of the pyridodihydropyrazinone compounds including substituent types (R1-R6), ring fusion configurations, and stereochemical arrangements. These parameter changes enable the optimization of PLK1 inhibition potency and selectivity. For example, different substituents at positions R3, R4, and R5 are explored to enhance binding affinity to the PLK1 kinase active site while maintaining manageable synthetic complexity.
2Reliability
If specific cell cycle kinases are inhibited to arrest cells in mitosis phase, then cell proliferation is controlled, but off-target effects and toxicity may increase
Solution Approach 1:
The pyridodihydropyrazinone compounds exhibit local quality through their specific binding affinity for PLK1 kinase versus other cell cycle kinases. The molecular structure contains specific functional groups and spatial arrangements that create a complementary fit for the PLK1 active site, allowing selective inhibition. This local molecular recognition capability enables potent PLK1 inhibition (IC50 values in the nanomolar to low micromolar range) while minimizing off-target effects on other kinases, thereby reducing unwanted off-target effects and toxicity.
Data Source
AI summary
Disclosed are pyridodihydropyrazinone compounds, processes for preparing them and their use as pharmaceutical compositions. The compounds according to the invention correspond to general formula (I),while the groups L, R1, R2, R3, R4 and R5 may have the meanings given in the claims and specification.